$25.63
1.42% yesterday
Nasdaq, Sep 04, 10:00 pm CET
ISIN
US90184D1000
Symbol
TWST

Twist Bioscience Corp. Stock News

Neutral
Business Wire
2 days ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the Baird 2025 Global Healthcare Conference on Tuesday, September 9, 2025 at 9:40 am Eastern Time in New York City. The company will also host one-on-one meeti...
Neutral
Business Wire
3 days ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it has collaborated with next generation therapeutics company, Synthetic Design Lab (SDL). “With our high throughput expertise, from novel binder discovery services to high throughput screening capabilities, we're able to support researchers...
Negative
Seeking Alpha
8 days ago
mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery challenges and limited efficacy for cancer and infectious diseases, make mRNA-focused biotechs unattractive compared to broader biotech opportunities. Investors seeking exposure should consider 'pic...
Neutral
Business Wire
17 days ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity, in the life sciences segment of the health care sector, today launched the Twist Oncology DNA Comprehensive Genomic Profiling (CGP) Panel, a customizable, research-use-only solution designed to empower users to identify genomic alterations for a broad set of tumors,...
Negative
Seeking Alpha
23 days ago
Twist Bioscience's growth continues to moderate, in part due to macro headwinds. While Twist's focus on transitioning to profitability in the near-term has significantly reduced cash burn, it has also taken much of the upside off the table. Twist's NGS business continues to be a growth driver, but much of this is already reflected in the share price.
Neutral
Business Wire
30 days ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth equity, today announced the appointment of Trynka Shineman Blake to its board of directors. She will also serve as a member of the audit committee. Ms. Shineman Blake most recently served as chief executive officer of Vistaprint, a Cimpress company, and brings nearly three decades of...
Neutral
Seeking Alpha
about one month ago
Twist Bioscience Corporation (NASDAQ:TWST ) Q3 2025 Earnings Conference Call August 4, 2025 8:00 AM ET Company Participants Adam Laponis - Chief Financial Officer Angela Bitting - Chief Corporate Responsibility Officer & Senior VP of Corporate Affairs Emily Marine Leproust - Co-Founder, Board Chair & CEO Patrick John Finn - President & COO Conference Call Participants Chad M. Wiatrowski - TD Co...
Positive
The Motley Fool
about one month ago
Twist Bioscience (TWST) Q3 Profit Surges

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today